Revolution Medicines
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Revolution Medicines sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Revolution Medicines: 16 sponsored US clinical trials, 11 recruiting.
Revolution Medicines sponsors 16 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 3 completed. 5 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-small Cell Lung Cancer (NSCLC), with 7 trials.
Top-decile sponsor footprint
Revolution Medicines ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
16 total, page 1 of 1
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
NCT05462717
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
NCT04774952
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
NCT03989115
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 1 |
| Phase 3 | 5 |
What is open in the Revolution Medicines pipeline
11 recruiting of 16 indexed (69% open); 3 completed (19%).
Phase mix: 5 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Non-small Cell Lung Cancer (NSCLC) (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Revolution Medicines: open-pipeline peers nationwide
Peers matched on 16 registered trials and 69% open enrollment, not the therapeutic-area sidebar.
Revolution Medicines sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 69% open enrollment (± trial volume)
- CorEvitas · 69% recruiting · 13 trials
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
Related
What to do with this Revolution Medicines page
16 registered trials is a research-attention snapshot, not an endorsement of Revolution Medicines or any single study.
- 11 of Revolution Medicines's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-small Cell Lung Cancer (NSCLC) is the condition Revolution Medicines studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-small Cell Lung Cancer (NSCLC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Revolution Medicines pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.